ROCO
4911
Market cap60mUSD
Oct 08, Last price
28.00TWD
1D
0.00%
1Q
-13.31%
Jan 2017
-65.04%
IPO
-59.80%
Name
G&E Herbal Biotechnology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
G&E Herbal Biotechnology Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the innovation and commercialization of advanced botanical extraction technologies and the products derived from them. Its diverse portfolio features a range of botanical anti-aging cosmetic items, including facial foam cleansers, cleansing essences, toners, lightening lotions, essential oils, and moisturizing serums and creams, along with specialized products like the SR-100 botanical essence and bromelain illuminating cleansing mousse. The company also manufactures capsules designed as hepato-protective agents. In the realm of wellness, G&E offers a selection of botanical healthcare products such as ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules, as well as various products catering to adults. Looking to its future developments, the company is actively pursuing new treatments, including Solarise injection for gynecologic, head, and neck cancers; Apocin capsules intended for non-small cell lung cancer; and SR-T100 Gel, which targets common and genital warts. Beyond its own product lines, G&E Herbal Biotechnology is involved in creating manufacturing technologies for a wide array of dietary supplements and provides expert technical advisory services to other biotechnology organizations. The company was founded in 2002 and is headquartered in Tainan City, Taiwan.
Key people
Guohua Guo
Chairman of the Board, Chief Executive Officer-Product Quality, General Manager · since 2002
Zhangyi Hong
Head of Finance & Accounting · since 2018
Nafen Zhang
Corporate Governance Officer · since 2024
Zhouyu Guo
Director · since 2025
Chongwen Lin
Director · since 2025
Shuwen Wu
Director · since 2018
Junnong Huang
Independent Director · since 2018
Zhengnan Huang
Independent Director · since 2025
Nenghui Lin
Independent Director · since 2019
Kangting Lin
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||